2 0 2 5年3月，刚满4 0岁的容德明（Dh imo y ROY）重返上海——这片曾开启他全球美妆科研征 程的起点。此时，他刚刚履新欧莱雅北亚研发与创新中心副总裁，而位于上海浦东、拥有4 0 0 多位科学家、端到端研发链路的欧莱雅中国研发中心，也正迎来成立2 0周年的里程碑。 将时间的指针拨回2 0 1 2年。2 6岁的容德明初抵中国，以洗护研究员身份加入欧莱雅。彼时， 中国的美妆市场正以每年超过2 0%的速度野蛮生长，"市场潜力" "消费升级"仍是行业热议的焦 点。 十三年风云激荡，如今的中国市场已突破万亿规模，不仅成为国际美妆巨头的战略要塞，更跃 升为全球科技创新的策源地。最新发布的《2 0 2 5自然指数—科研城市》显示，全球科研十强 城市中，中国独占六席；商务部数据更揭示，2 0 2 2至2 0 2 4年间，高技术产业新设外资企业从 1 0 0 1 9家跃升至1 5 2 1 2家，科研技术服务跻身外商投资三大主力方向。 当扎根中国二十载的研发中心，与历经五国科研工作淬炼的容德明再度交汇，一场以中国为核 心的"协同创新"远征就此启航。 " 我 回 到 的 是 一 个 全 新 的 中 国 ， 它 已 ...

为此，欧莱雅科研人员从结构改变、代谢功能紊乱、信号传导障碍3大方向，将DNA不稳定、 表观遗传学改变、微生态失衡等9大皮肤相关路径整合为一个与皮肤长寿深度关联的"美妆长寿 之轮"。 从科研转化的角度来看，欧莱雅集团以此为抓手系统性整合过去所有的皮肤抗老科研的相关成 果，形成一个大而全的基础研究体系壁垒，并迅速为旗下品牌接入更多与之相关的技术成果， 快速抓住新的成分和市场热点。 技术"定价"时代，科技创新潮流始终是全行业关注的焦点。 辞旧迎新之际，我们不仅看到长寿科学在改变美妆科研的底层逻辑，也看到AI正加速升级科研 效 率 。 面 向 将 至 的 2 0 2 6 ， 我 们 也 发 出 疑 问 ， PDRN 在 市 场 的 大 火 是 否 会 掀 起 新 一 轮 的 成 分 热 潮？胶原蛋白和多肽类成分还有哪些深度挖掘空间，越来越多企业开始布局感官科学，又在释 放怎样的信号…… 然而，一个个巨大问号的背后，在概念和技术风潮之外，或许我们最应该讨论的其实是，美妆 科研与消费者关系的质变方式，以及产品价值交付的全新模型。 长寿科学正在以肉眼可见的速度，改写美妆科研的底层逻辑。 南方科技大学医学院/前沿生物技术研究 ...

Core Insights - Deep Longevity, Inc. has appointed Dylan Kay as Chief Business Officer and Luke Shaffer as Vice President of Sales for the United States, effective January 1, 2026, marking its entry into the U.S. health market [1] - The company plans to launch its commercial operations in the first quarter of 2026, focusing on four key areas: corporate health and wellness programs, health insurance and risk-bearing entities, diagnostic laboratories and longevity clinics, and high-end consumer health platforms [1] - Deep Longevity aims to sign over 50 U.S. corporate clients by the end of 2026, positioning its aging clock technology at the center of the preventive healthcare revolution [2] Company Strategy - The appointments of Kay and Shaffer are strategic moves to leverage their extensive experience in health technology and corporate partnerships to drive growth [1][2] - Deep Longevity's clinically validated aging clocks, including BloodAge, EpigeneticAge, MindAge, BiometricAge, and the upcoming FaceAge, provide actionable insights across molecular, physiological, cognitive, and psychological aging dimensions [1] - The company's SaaS solutions enable employers and insurance companies to transition from passive disease care to proactive, quantifiable personalized longevity programs that can extend healthy lifespan and reduce long-term costs [1] Market Context - The U.S. healthcare expenditure is approximately $4.5 trillion annually, with 90% attributed to chronic diseases, highlighting the significant market opportunity for Deep Longevity's solutions [2] - The leadership of Kay and Shaffer is expected to transform emerging science into enterprise-level impact, aligning with the growing focus on preventive healthcare [2]

Core Insights - Deep Longevity, Inc. has appointed Dylan Kay as Chief Business Officer and Luke Shaffer as Vice President of Sales for the U.S. market, effective January 1, 2026, indicating a strategic move to penetrate the U.S. health market [1] Group 1 - The appointment of new executives signifies Deep Longevity's commitment to expanding its presence in the largest health market globally [1] - The company plans to initiate commercial operations in the first quarter of 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：���） 自願性更新營運情況 Deep Longevity於美國的業務擴展及 啟動二零二六年前委任主要高管 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本 公 司 今 日 宣 佈，全 球 可 解 釋 人 工 智 能 驅 動 老 化 時 鐘 與 長 壽 科 學 的 領 導 者 Deep Longevity, Inc及其附屬公司（統稱「Deep Longevity」）委任Dylan Kay為 美利堅合眾國（「美國」）首席商務官及Luke Shaffer為美國銷售副總裁，二人均將於 二零二六年一月一日正式履新。 此次委聘標誌著Deep Longevity積極進駐全球最大的健康市場 － 美國，且已定於 二零二六年第一季度啟動商業 ...

Core Viewpoint - The stock price of Lattice Technology (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting the rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lattice Technology's stock has shown significant growth, with a current increase of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity in the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - The stock of Lijing Pacific (00575) experienced a significant increase, rising over 12% yesterday and more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting a rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lijing Pacific's stock price has shown a remarkable increase, with a current rise of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity within the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market, which Deep Longevity aims to enter, is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - The stock price of Lattice Technology Pacific (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD [1] Company Summary - Lattice Technology Pacific announced that its wholly-owned subsidiary, Deep Longevity, a leader in AI-driven aging clocks and longevity science, will initiate an expansion plan into the U.S. market in the first quarter of next year [1] - This expansion will position Deep Longevity in the core of the largest and fastest-growing health market globally, which is currently valued at over 6.8 trillion USD [1]

Core Viewpoint - The article highlights the innovative strategies and leadership of Barbara Lavernos at L'Oréal, emphasizing the company's commitment to research and development as a key driver for future growth in the beauty industry [2][3][4]. Group 1: Leadership and Innovation - Barbara Lavernos has been pivotal in L'Oréal's transformation, overseeing a research team of over 4,000 scientists and managing an annual R&D budget exceeding €130 million (approximately 1.1 billion RMB) [4][6]. - Under her leadership, L'Oréal has launched over 3,000 new products annually, contributing 10% to 15% of the company's revenue from new products [6][7]. - The company has maintained a strong focus on quality, safety, and performance in its products, with a significant emphasis on patent applications as a measure of innovation [7][11]. Group 2: Research and Development Focus - L'Oréal's R&D strategy includes investments in life sciences, artificial intelligence, beauty technology, and sustainability, with a notable increase in patent applications, reaching 694 in 2024 [11][12]. - The company has established a comprehensive technology matrix for its "New Age Beauty" initiative, integrating cutting-edge research into consumer products [17][20]. - L'Oréal's Chinese R&D center has been instrumental in driving innovation, with 372 patent applications filed in 2024, showcasing the center's significant contributions to the company's global innovation strategy [24][31]. Group 3: Strategic Initiatives - The BIG BANG initiative launched in China aims to foster open innovation by collaborating with promising startups in AI, biotechnology, and pharmaceutical technology [29][30]. - L'Oréal's commitment to long-term research in longevity science positions it as a leader in the beauty industry's future, focusing on the aging process and its implications for skincare [14][15]. - The integration of AI into L'Oréal's R&D processes has significantly accelerated product development, allowing for the evaluation of 150 molecules in a fraction of the time previously required [21][22].

（於開曼群島註冊成立之有限公司） （股份代號：���） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Deep Longevity, Inc（本公司之全資附屬公司）連同其附屬公司研發在分子、細 胞、器官及心理層面追蹤人類老化的可解釋之人工智能系統。Deep Longevity的 專利深層老化時鐘為消費者、醫生及企業提供垂直型軟件即服務(SaaS)©解決方 案，提供經證實可改善健康狀況並延長健康壽命的個人化建議。更多資訊請瀏覽 www.deeplongevity.com。 自願性更新營運情況 Deep Longevity於二零二六年第一季度戰略進駐美國市場 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本公司今日宣佈，全球可解釋人工智能驅動老化時鐘與長壽科學的領導者Deep Longevity, Inc及其附屬公司 ...